Homick J L, Kohl R L, Reschke M F, Degioanni J, Cintron-Trevino N M
Aviat Space Environ Med. 1983 Nov;54(11):994-1000.
This study evaluated the time course of efficacy of transdermal scopolamine in the prevention of motion sickness induced by exposure to coriolis stimulation in a rotating chair. We measured levels of efficacy, quantified side effects and symptoms, and determined inter- and intra-subject variability following use of transdermal scopolamine. The response to transdermal scopolamine was highly variable, although overall we recorded a 40% improvement (p less than 0.05) in test scores 16-72 h after application of the transdermal system. This variability could not be explained solely by the levels of scopolamine present in the blood. The improvement was not due to the artifactual repression by scopolamine of selected symptoms of motion sickness. An unexpectedly high incidence of side effects was reported. It was concluded that the therapeutic use of transdermal scopolamine be evaluated individually and that individuals be cautioned that subsequent usage may not always be effective.
本研究评估了透皮东莨菪碱预防旋转椅中科里奥利刺激诱发晕动病的疗效时间进程。我们测量了疗效水平，对副作用和症状进行了量化，并确定了使用透皮东莨菪碱后的个体间和个体内变异性。尽管总体上我们记录到在应用透皮系统后16 - 72小时测试分数有40%的改善（p小于0.05），但对透皮东莨菪碱的反应高度可变。这种变异性不能仅由血液中存在的东莨菪碱水平来解释。这种改善并非由于东莨菪碱对所选晕动病症状的人为抑制。报告了意外高的副作用发生率。得出的结论是，透皮东莨菪碱的治疗用途应个体评估，并且应告诫个体后续使用可能并非总是有效。
